# Fubon Bank

> Fubon Bank is a VC fund in Central backing Financial Services, Banking and FinTech. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Central, Hong Kong
- Total investments: 4
- Last investment: Jan 2026
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.fubonbank.com.hk

Fubon Bank is a VC fund in Central focused on Financial Services and Banking. Fubon Bank is providing a wide range of financial services encompassing consumer and wholesale banking and investment services. Fubon Bank (Hong Kong) Limited ("Fubon Bank") is a wholly owned subsidiary of Fubon Financial Holding Co., Ltd. ("Fubon Financial Holdings"), one of the largest financial holding companies in Taiwan.Fubon Financial Holdings is now the only Taiwanese financial institution with banking subsidiaries in China, Taiwan and Hong Kong. Fubon Financial Holdings acquired a 75% stake from the Bank's former shareholders, Arab Banking Corporation (B.S.C.) and China Everbright Limited in April 2004. The Bank formally adopted the name Fubon Bank on 6 April 2005. Following the successful privatization of the Bank by Fubon Financial Holdings, Fubon Bank became a wholly owned subsidiary of Fubon Financial Holdings in June 2011.Fubon Bank operates 22 branches and 2 Securities Services Centres in Hong Kong, providing a wide range of financial services encompassing consumer and wholesale banking, wealth management, financial markets, securities brokerage and investment services. Fubon Bank holds an A-2 short-term, BBB+ long-term rating from Standard & Poor's. The rating reflects Fubon Bank's strong capitalization, good liquidity and sound asset quality.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Financial Services | 2 | 50% |
| Banking | 1 | 25% |
| FinTech | 1 | 25% |
| Finance | 1 | 25% |
| Health Care | 1 | 25% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 2 | 50% |
| Post-IPO Debt | 1 | 25% |
| Debt Financing | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Hong Kong | 2 | 50% |
| Singapore | 1 | 25% |
| United States | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| WeLab | WeLab is reinventing traditional financial services by creating seamless digital experiences. With the company's proprietary risk management technology, WeLab effectively analyzes unstructured mobile big data within seconds to provide innovative financial services and offer consumer financing solutions for individual customers. WeLab alsooffers B2B enterprise solutions by partnering with traditional financial institutions, which utilize WeLab’s technology to offer fintech-enabled services to their customers. | $220M | Series D | Jan 15, 2026 |  |
| Atome | Atome is a "buy now, pay later" brand that splits consumers' bills into three equal, zero interest payments over time. | $145M | Debt Financing | Jan 12, 2026 |  |
| New World Development | New World Development Company Limited (“the Group”, Hong Kong stock code: 00017), a premium brand infused with a unique personality defined by The Artisanal Movement, was founded in 1970 and was publicly listed in Hong Kong in 1972. It is a constituent stock of the Hong Kong Hang Seng Index, with a total asset value of HK$392.1 billion as at 30June 2016. Our core business areas include property development, infrastructure and services, retail, and hotels and serviced apartments, boasting operations in Hong Kong, Mainland China, Macau and numerous major cities. | $11.2B | Post-IPO Debt | May 22, 2025 |  |
| Optimer Pharmaceuticals | Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer's development efforts are focused on products that treat gastrointestinal infections, andrelated diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88. | $22.2M | Series D | Dec 14, 2005 |  |

4 of 4 investments shown.

## Co-investors
- [HSBC](https://shizune.co/investors/profile/hsbc) — VC Fund, 3 deals together
- [Allianz X](https://shizune.co/investors/profile/allianz-x) — VC Fund, 2 deals together
- Baiduri Bank — VC Fund, 1 deal together
- [Bank of China](https://shizune.co/investors/profile/bank-of-china) — VC Fund, 1 deal together
- [BB Biotech Ventures](https://shizune.co/investors/profile/bb-biotech-ventures) — VC Fund, 1 deal together
- [Cathay United Bank](https://shizune.co/investors/profile/cathay-united-bank) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does Fubon Bank invest in?

Fubon Bank invests primarily in Financial Services, Banking and FinTech startups, most often at Series D and Post-IPO Debt stage. Most of the 4 investments tracked by Shizune back companies in Hong Kong. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Fubon Bank last invest?

The most recent investment recorded for Fubon Bank closed in Jan 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co